<DOC>
	<DOCNO>NCT02768714</DOCNO>
	<brief_summary>This Phase III , randomise , assessor-blind , parallel group , multicentre trial . At least 180 adult subject high-risk Stage II Stage III / IV breast cancer randomise ( 1:1 ) receive either Eurofarma 's pegfilgrastim ( n = 90 ) Neulastim ( n = 90 ) 8 10 site Brazil . Subjects undergo maximum 4 cycle myelosuppressive chemotherapy ( 21 day per cycle ) .</brief_summary>
	<brief_title>Trial Compare Efficacy Safety Pegfilgrastim Biosimilar Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Males females ≥ 18 year age ( time sign consent ) 3 . Breast cancer highrisk Stage II , Stage III , Stage IV ( classification accord American Joint Committee Cancer ) 4 . Eligible receive 4 cycle docetaxel doxorubicin combination CTX treatment highrisk stage II , III , IV breast cancer 5 . CTXnaïve 6 . ECOG performance status ≤ 2 7 . Adequate bone marrow function : Leucocyte count &lt; 50 x 109/L ANC ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Haemoglobin ≥ 10 x g/dL 8 . Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % echocardiography equivalent method ( e.g . Multi Gated Acquisition scan ) within 4 week prior administration first dose trial medication 9 . Alanine aminotransferase aspartate aminotransferase &lt; 2.5 x upper limit normal ( ULN ) , alkaline phosphatase &lt; 5 x ULN 10 . Total bilirubin ≤ ULN 11 . Creatinine ≤ 1.5 x ULN 12 . Female subject childbearing potential must negative serum pregnancy test within 14 day first dose trial treatment agree use highly effective contraception ( e.g . hormonal contraception intrauterine device [ establish prior start trial ] , plus usage least 1 partner additional spermicidecontaining barrier method contraception ) 2 week prior administration first dose trial medication trial completion , 30 day last dose trial drug 13 . Female subject nonchildbearing potential must document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . A male subject female partner childbearing potential must either prior vasectomy agree use effective contraception 2 week prior administration first dose trial medication trial completion , 30 day last dose trial drug 14 . Able comply trial Protocol . 1 . Severe chronic neutropenia 2 . History chronic myeloid leukaemia myelodysplastic syndrome 3 . History sickle cell disease 4 . Previous concurrent malignancy except noninvasive nonmelanomatous skin cancer , situ carcinoma cervix , solid tumour treat curatively , without evidence recurrence least 10 year prior trial entry 5 . Active uncontrolled infection 6 . Known human immunodeficiency virus seropositivity ; active hepatitis B hepatitis C Screening Visit 7 . Clinically significant impairment LVEF 8 . Severe valvular heart disease , myocardial infarction , heart failure , unstable angina pectoris , uncontrolled hypertension , uncontrolled arrhythmia within 6 month Screening Visit 9 . Significant neurologic psychiatric disorder include psychotic disorder , dementia , seizure would prohibit understanding give informed consent 10 . Concurrent prior radiotherapy within 4 week Screening Visit 11 . Tumour surgery within 4 week prior administration first dose trial medication 12 . Concurrent prior anticancer treatment breast cancer endocrine therapy , immunotherapy , monoclonal antibody , and/or biological therapy 13 . Concurrent prophylactic antibiotic antibiotic treatment within 72 hour CTX 14 . Prior bone marrow stem cell transplant 15 . Previous therapy recombinant human granulocyte colony stimulate factor ( G CSF ) product 16 . Known hypersensitivity docetaxel , doxorubicin , pegfilgrastim , filgrastim , Escherichia coli protein , excipients use trial medication 17 . Treatment lithium randomization 18 . Known controlled drug addiction , include alcoholism 19 . Participation clinical trial within 30 day prior Screening Visit 20 . Pregnant nursing woman , woman plan become pregnant , woman childbearing potential agree use highly effective contraception ( e.g . hormonal contraception intrauterine device [ establish prior start trial ] , plus usage least 1 partner additional spermicidecontaining barrier method contraception ) 2 week prior administration first dose trial medication trial completion 30 day last dose trial drug 21 . Male subject female partner childbearing potential prior vasectomy agree use highly effective contraception 2 week prior administration first dose trial medication trial completion 30 day last dose trial drug 22 . Any severe concurrent disease condition , judgment Investigator would make subject inappropriate trial participation . 23 . Peripheral neuropathy ( sensory/motor ) Grade 2 high ( CTCAE , Version 4.03 ) 24 . Chronic use corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Breast Cancer High risk Stage II Stage III / IV</keyword>
</DOC>